Clinical trial · Observational
Gastric Cancer Survival Without Chemotherapy
Development of a Staging System and Survival Prediction Model for Advanced Gastric Cancer Patients Without Adjuvant Treatment After Curative Gastrectomy
NCT05125614CI-TRIAL-00055281completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is observational study to analyze the actual overall survival of the patients who did not receive adjuvant chemotherapy after curative gastrectomy for gastric cancer. The investigators developed prediction model for the overall survival of these patients and validated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No adjuvant chemotherapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Developement set
- description
- Gastric cancer patients who did not receive adjuvant chemotherapy after curative gastrectomy from 2009 to 2016 at Seoul St.Mary's Hospital
- interventionNames
- Other: No adjuvant chemotherapy
- label
- Validation set
- description
- Gastric cancer patients who did not receive adjuvant chemotherapy after curative gastrectomy from 2009 to 2016 at St.Vincent''s Hospital
- interventionNames
- Other: No adjuvant chemotherapy
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- June-01-2021
- description
- Overall survival of the patients
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * histologically confirmed primary gastric adenocarcinoma * curative R0 resection with D2 lymph node dissection * pathologic stage II or III gastric cancer Exclusion Criteria: * Patients who received neoadjuvant or AC treatment * follow-up loss or death within 30 days of surgery * completion of total gastrectomy * other malignancy within 5 years before gastrectomy
References
Publications (0)
Data not yet available
No reference posted for this study.